Skip to main content

Table 3 Left ventricular ejection fraction before CTO-PCI and during follow-up

From: Impact of coronary collateralization on long-term clinical outcomes in type 2 diabetic patients after successful recanalization of chronic total occlusion

VariableAll patients (n = 533)Non-diabetes (n = 335) (63%)Diabetes (n = 198) (37%)p value (non-T2DM vs T2DM)
AllGood CC (n = 237)Poor CC (n = 98)p valueAllGood CC (n = 118)Poor CC (n = 80)p value
LVEF (%) at baseline52.39 ± 7.3853.00 ± 7.2753.52 ± 6.8151.74 ± 8.180.04251.36 ± 7.4651.70 ± 7.4850.85 ± 7.440.4310.013
LVEF (%) at follow-up54.89 ± 6.5455.72 ± 6.1856.62 ± 5.7353.54 ± 6.71< 0.00153.49 ± 6.8954.17 ± 6.5652.50 ± 7.290.095< 0.001
ΔLVEF (%)2.50 ± 4.632.72 ± 4.823.10 ± 4.751.80 ± 4.870.0242.14 ± 4.292.47 ± 4.221.65 ± 4.370.190.163
p value (baseline vs follow-up)< 0.001< 0.001< 0.001< 0.001 < 0.001< 0.001< 0.001  
  1. T2DM type 2 diabetes mellitus, CC coronary collateralization, CTO chronic total occlusion, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, ΔLVEF change in eft ventricular ejection fraction